Sardomozide

Drug Profile

Sardomozide

Alternative Names: CGP 48664; CGP 48664A; SAM 486

Latest Information Update: 15 Jun 2009

Price : $50

At a glance

  • Originator Novartis
  • Class Amidines; Antineoplastics; Indans
  • Mechanism of Action Adenosylmethionine decarboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 06 May 2004 A study has been added to the adverse events and Cancer therapeutic trials sections
  • 27 Sep 2000 A phase II study in non-Hodgkin's lymphoma has been added to the therapeutic trials and adverse events sections
  • 27 Sep 2000 Phase-II clinical trials for Non-Hodgkin's lymphoma in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top